OBJECTIVES: Based on the pharmacoeconomic analysis determine the feasibility of vaccine against HPV-associated diseases in Kazakhstan. METHODS: The number of prevented cases of HPV-related diseases, disability, death, and the size of damage avoided due to vaccination was determined using static pharmacoeconomic MS Excel model which focuses on 4 types of HPV-associated diseases that are targeted by the vaccine “Cervarix” (ASCUS, cervical intraepithelial neoplasia of grades 1, 2, 3 and cervical cancer), 2 outcomes of CC - disability and death. Number of CC cases expected in the cohort for the period of survival was determined based on the relative incidence rates (16.0 per 100 000 female population in Kazakhstan), the cohort of 12 year old girls (122799), and the life expectancy in Kazakhstan (73 years). To determine the value of the case of HPV-associated diseases, medical technologies used in CC, CIN 1, CIN2, CIN3, ASCUS, the frequency of their use and the price for the services were determined. RESULTS: Vaccination cost for cohort of girls (122799) resulted in 23.2 million USD. The cost of prevented damage is estimated 16.5 million. Additional cost - 6.7 million. Years of life saved - 11172. The coefficient of "cost-effectiveness" of using Cervarix vaccine was calculated for 598 USD for one year of life saved. The cost of prevented damage was identified to be 38.5 million based on the number of prevented cases of CC, CIN 1, CIN2, CIN3, ASCUS and the cost of each case of illness, disability, and death. CONCLUSIONS: The cost of potential annual preventative damage/gain as a result of Cervarix vaccine application may reach 38.5 million USD. When comparing the annual preventative damage to the annual cost of vaccination for 12 year old girls in Kazakhstan, the cost of prevention was estimated to be 1.7 times more than the cost of one vaccine cohort.